WO2015030567A1 - Improvements to a complementary formulation for counteracting adverse effects of cancer treatments and of treatments for some viral diseases - Google Patents

Abstract

The invention relates to improvements to a diluted pharmaceutical formulation comprising at least one component of plant, animal and mineral origin, such that said formulation includes Abrotanum as a diluted component of plant origin, Sepia as an diluted component of animal origin, and Phosphorus and Causticum Hahnemanni as diluted components of mineral origin. The formulation is used to counteract and alleviate the adverse effects of radiotherapy, and the adverse effects of treatments using anti-viral medication and/or interferons.

Description

 IMPROVEMENTS TO AUXILIARY FORMULATION TO COUNTER ADVERSE EFFECTS OF TREATMENTS AGAINST CANCER AND TREATMENT AGAINST SOME VIRAL DISEASES FIELD OF THE INVENTION

The present invention relates generally to the field of medicine. More particularly, it refers to the use of a diluted drug formulation made on the traces of the multiple components of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsidas, Liliopsidas, Equisetopsidas, Lycopodiopsidas and Pinopsidas; of animal origin where we find insects, nosodes and organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), Krebs cycle catalysts and amino acids, useful to minimize or alleviate the different adverse effects that occur later to the administration of chemotherapy and radiotherapy in the treatment of cancer, as well as the side effects caused by antiviral medications and interferons.

BACKGROUND OF THE INVENTION

It is common knowledge that in recent years the suffering of different types of cancer, hepatitis C and HIV, have proliferated very rapidly in all sectors of the population.

 In most cases of cancer, these patients are treated with surgery, chemotherapy and / or radiotherapy. There are variants in the substances and radiation application, in each case, which are used depending on the type of cancer, progress and response of the patient to each type and intensity of treatment.

 Chemotherapy treatments are aimed at destroying cancer cells, unfortunately they cannot distinguish them from healthy cells, causing adverse effects that can be from a series of discomforts that decrease the patient's quality of life, producing such harmful effects that they put risk the continuity of the treatment and the patient's life itself. The most common symptoms range from: hair loss, nausea, vomiting, diarrhea, constipation, myalgia, arthralgia, even severe tachycardias.

Radiation therapy offers important advantages for local and regional treatment of malignant processes. Radiation therapy produces its biological effect through the formation of pairs of reactive oxygen ions or metabolites such as superoxide, H202, or hydroxyl radicals, products that cause DNA breakdown, which if not repaired can lead to cell death. Among other recognized late effects of radiation therapy, it is worth mentioning the mutagenesis and carcinogenesis produced by the sub-lethal effects of DNA radiation Radiation therapy can be administered in the form of electromagnetic waves, such as X-rays or gamma rays or as a current or flow of particles such as heavy ions, protons, neutrons, pi mesons or electrons. The characteristics of each of these forms of radiation have important implications for their clinical use. Low-energy or kilo-voltage X-rays produce their energy easily as they pass through the tissue, and consequently cause considerable damage to the skin and normal tissues overlying deep tumors. X-rays with higher energy generated by linear accelerators and gamma radiation generated by a 6OC0 pump, cause less damage to the skin, which represents a great advantage in the treatment of visceral tumors such as gastrointestinal carcinomas, brain tumors or carcinoma of lung

Radiation therapy, while eliminating diseased cells, can affect healthy tissues near the treatment area and as a consequence side effects may occur, due to the fact that in its path through the body, radiation transmits part of its energy to the Cell DNA, the genetic code molecule, causing irreversible damage that ends up killing the cell. This happens in both normal and cancer cells.

The side effects of radiotherapy are difficult to predict with accuracy, since they depend on multiple factors such as the area of the organism where the treatment is performed, the dose, the fractionation and the individual susceptibility of each person; in fact, in some cases minimal effects occur, while in others, they are more serious and medical treatment is necessary to control them.

 Among the side effects we can find: fatigue, inflammation, difficulty swallowing, urinary and bladder changes, changes in the joints (elbow-knee), lymphedema, among others.

In the case of viral hepatitis through parental infection they have experienced an increase in hepatitis forms, especially HBV and HCV or mixed infection. This increase is directly related to an increase in the abuse of drugs that are applied intravenously, and that also happens as a form of HIV infection.

In the treatment of patients with acute and chronic viral hepatitis or HIV where they have a high activity of the infectious process with continuous viral replication, antiviral medications, Interferons and combinations of both are used. Adverse reactions are considerable: Increase in temperature, myalgia, arthralgia, headache, chills, vomiting, diarrhea, asthenia, drowsiness, attack on the general condition with weight loss due to loss of appetite, decrease in leukocytes and thrombocyte count, as well as toxic effects and depressions, etc.

On the other hand the drugs of the Interferon group have a negative influence on the liver and the whole organism. 75-80% of patients treated with this type of medicine develop a Toxic hepatitis, whose evolution is dangerous for the patient's life. Similarly, the frequency and intensity of adverse reactions of antiviral medications cause additional liver overload, producing adverse effects such as: hepatic steatosis (excess fat in the liver), hepatomegalies (increased liver volume), hepatitis (inflammation of the liver), proximal renal tubular alteration, lactic acidosis (accumulation of lactic acid in the blood) and peripheral neuropathy (involvement of the peripheral nerves). Thus, it can be considered that the antiviral drugs used against viral hepatitis and HIV have similar adverse effects with some types of chemotherapies used as a base treatment for some types of cancers. Both therapeutic groups in both antiviral drugs and chemotherapy often share the same enzymatic pathways and cellular receptors as a mechanism of pharmacological action which these can compete with each other and can block enzymes or substrates that participate in the different pathways or sites of cellular metabolism, in the cell cycle (controlling or affecting the manipulation of the structure of the RNA and DNA necessary for cell replication), or on the cell membrane; producing that there is a lower capacity of cellular response and reflected in the metabolism of the same, which present metabolic dysfunctions and blockages in the energy producing systems manifesting itself with physical changes in the quality of life.

Currently to counteract some of the side effects of chemotherapy, radiotherapy and treatments with antivirals and interferons, it they use different drugs among which you can find a combination of dexamethasone (a type of spheroid) and a ^' serotonin blocker ^' also known as -setrons- a compound that prevents the natural substance serotonin from sending vomit messages to the brain, blockers Serotonin include dolasetron, granisetron, ondansetron and palonosetron and can be used to treat nausea and vomiting.

 Within the control of side effects is also used Furosemide auxiliary against fluid retention, Prednisone and some pain relievers that help reduce inflammation and pain when they are present, The problem of using these drugs is that apart from not eliminating greatly measure the annoying effects, in turn produce other adverse effects in the patient and if one does not work you should try at least with another, as there are patients especially sensitive to one substance, but resistant to another.

 These medications only focus on the symptoms, and do not take into account the damages that the organism suffers from the toxicity of the components of chemotherapy and some antivirals.

 Patients with cancer, hepatitis C and HIV have special needs. First of all it is important to observe the need to support them with some complementary or integral therapy, in a natural way that allows them to maintain it with a good quality of life during and after the application of chemotherapy, radiotherapy or treatments with antivirals and interferons.

DETAILED DESCRIPTION OF THE INVENTION It is important to note that the root of the side effects of chemotherapy, radiotherapy and treatments with antivirals and interferons, is the damage that cells of different organs are suffering, therefore the present invention provides a route for relief or elimination of toxicity by chemotherapy, radiotherapy and by antiviral drugs and interferons, involving administering a composition comprising dilutions of multiple traces of different components of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsidas, Liliopsidas, Equisetopsidas , Lycopodiopsidas and Pinopsidas; of animal origin where we find insects, Nosodes and Organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids, made using diluted components which are combined, generating a effect within our body, so it finally acts as an antihomotoxic medicine that helps improve the health or well-being of the person who consumes them.

Classic homeopathy uses unit medicines, of which only a part are really remedies consisting of a single substance (for example, sulfur, mercury, arsenic, etc.) or are plant extracts that contain a very complex mixture of various substances. The so-called repertoires (lists of symptoms produced by medications) that makes it easier for homeopaths to choose the most appropriate medications in each case. Antihomotoxic drugs mainly constitute mixtures of substances in low or medium potency (homeopathic dilutions). The difference with traditional homeopathy is that homotoxicology, in addition to using classic homeopathy medicines, uses completely new homeopaths such as: Nodes: viral, bacterial, vaccines, tissues or organs with pathological alterations, blood secretions and endocrine secretions, homeopathic allopathic medicines, intermediate catalysts: citric acid cycle acids, quinones and others; and organopreparations: elaborated homeopathically from organic tissues from healthy pigs. Also in the same antihomotoxic medicine incorporates different substances and in different dilutions.

Therefore, given the way in which an antihomotoxic drug is previously elaborated, it is capable of stimulating the structure of the organ, the function and the mental aspect of the individual, as well as the stimulation of blocked enzyme systems in degenerative diseases, the stimulation of defensive antitoxic mechanisms and generates an effect of tropism on damaged organs; he works on the # theory of the six phases that Reckeweg formulated, where he shows the chronological development of different symptoms of a disease in the framework of baseline regulation. Each phase is transformed fluidly into another and typical guide symptoms of each phase are observed. It should be mentioned that antihomotoxic medicine serves as a bridge between conventional allopathic medicine and homeopathy, in such a way that it is possible to homeopathize allopathic drugs thus removing its toxic effect and it can be combined with other components safely. Homotoxicology is the branch of medicine that studies in a scientific way, diseases caused by exogenous toxins (which are acquired from outside the body) and endogenous (those produced by the same organism) that block the cellular metabolic function of tissues and the organs of the human being. (Antihomotoxic Medicine Vol. I Principles, Clinical, Practical, 2004).

 The present invention, given the nature of its content and pharmacodynamic form as it acts, allows the patient's quality of life to be raised, eliminating or greatly diminishing the consequences of chemotherapy, radiotherapy and antiviral medications and interferons. It has the great advantage that can be combined with drugs that the patient may be taking for cancer, viral hepatitis, HIV or other diseases, without taking away from these drugs.

 Its biological effects naturally confer antiemetic, analgesic, antivertiginous, biological and decreased properties of asthenia and adinamia, which allow the application of the invention for a long period of time without causing sequelae or side effects characteristic of other medications used to mitigate the aforementioned adverse effects.

 The formula of this product is unique and its design applies to the principles of homeopathic dilution. This method allows four very important objectives to be achieved, among others:

The first is that it manages to combine 101 different components that act independently, stimulating various organs and tissues at the cellular level to prepare and recover from the toxic effects of Chemotherapy, receiving the least possible damage, and consequently greatly reducing adverse effects.

 Second, positive results are achieved using micro doses, without causing toxicity, adverse effects or contraindications with chemotherapy or other drugs.

 Third, as a result of these benefits, it can be used for long periods of time, without causing resistance or adverse reactions in the body.

 Fourth and of vital importance, this product yields benefits at the cellular, tissue, organic and mental levels, which avoids the cumulative deterioration in the patient's level of health by allowing him to continue his chemotherapy treatment without interruptions.

 It can be applied safely and effectively without causing toxicity, contraindications, side effects, risks of addiction or interaction with any medication.

The present invention aims at the preparation of a diluted medicated formulation comprising a mixture of dilutions of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsides, Liliopsides, Equisetopsides, Lycopodiopsides and Pinopsides; of animal origin where we find insects, Nosodes and Organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids, for the relief of symptoms of dizziness, nausea, vomiting, weakness of the body, headache, pain of body, feeling of heaviness of the head, feeling of heaviness of the body, sleep, diarrhea, constipation, bone and joint pain, chest and / or throat pain when eating, mouth sores, loss of appetite and gas or flatulence, which they occur after the administration of chemotherapy and / or radiotherapy in the treatment of cancer, as well as after the administration of antiviral drugs and interferons in the treatment of viral hepatitis and HIV.

 The present invention also aims at a medicament obtained from a diluted medicated formulation acceptable for the relief of symptoms of dizziness, nausea, vomiting, weakness of the body, headache, body aches, heaviness, headache, sensation of heaviness of body, sleep, diarrhea, constipation, bone and joint pain, chest and / or throat pain when eating, canker sores, loss of appetite and gas or flatulence, caused by the application of chemotherapy, radiotherapy and treatments with antiviral drugs and interferons, comprising a mixture of effective dilutions of plant origin that include one or more elements of each of the following classes of plants: Magnoliopsidas, Liliopsidas, Equisetopsidas, Lycopodiopsidas and Pinopsidas; of animal origin where we find insects, Nosodes and Organotherapeutics; and of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and by other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids.

The technique for making the dilutions necessary to obtain the formulation according to the present invention corresponds to the conventional technique of manufacturing homeopathic formulations according to the Homeopathic pharmacopoeia of the United States, which consists in diluting in pre-established proportions for each substance, a part of solute in others of solvent and applying to this dilution vigorous succuctions. For the purpose of the present invention for the dilutions the decimal scale is used where the dilution factor is 10, that is 1 part of dyeing in 9 parts of solvent, it is shaken vigorously and the second decimal dilution (2x) is obtained, considering that the tincture of which it is made corresponds to the first decimal dilution (1x). It continues like this, in the same way until the desired decimal dilution is obtained, always taking into account that to obtain a higher dilution it is always necessary to start from the previous dilution.

 Of these elements, the specific dilution that produced the effect of stimulation, modulation and inhibition was applied by applying the principle of Arndt-Schulz (Fundamental Biological Law) (Rudolf Arndt, psychiatrist, 1835-1900; Hugo Schulz, pharmacologist, 1853-1932 ) which establishes that low dilutions stimulate, medium dilutions modulate and high dilutions inhibit without suppressing the function of a system or organ.

Therefore we set out to investigate what dilution produces the effect of stimulation, modulation and inhibition, where some of these elements can be repeated in different powers, citing what Vosgerau mentioned: ^" If different powers of one are mixed and another drug, no potency will disturb the other ^" (Homotoxin Journal No.6, 1979, p.135-143).

If we make an analogy of an allopathic product where an antibiotic at very low concentrations will not generate the antimicrobial effect that is sought, that is, it needs a weight dose to produce the desired antimicrobial effect, in this way, our invention seeks in the same way generate a welfare effect, seeking the appropriate dilution for that effect.

 It has been shown that the components contained in the formulation lessen or inhibit the adverse effects that occur after the application of chemotherapy.

 Within the state of the art we can find the following documents:

"US 6'964,785" .- US patent with Korean priority claiming a herbaceous composition that effectively serves to improve the body's immune response and hematopoiesis, as well as reducing oxidative damage caused by cancer treatment. Add to its applications, the beneficial effect to treat patients with chronic degenerative diseases, weak and elderly.

 The formula is mainly composed of Angelicae gigantis and Cnidium root for medicinal use, whose process involves obtaining an extract from an infusion in hot water, characteristics that are not used in our invention since it is based on dilutions and not It contains none of the mentioned elements.

"US 7'025,993" and "US 7'534,455" .- US patents with international application in 2001 describing the natural formula that is used in conjunction with a chemotherapy treatment allowing to improve the patient's quality of life. These patents aim to increase the therapeutic index of chemotherapeutic drugs, to difference with our invention that is to eliminate or lessen the adverse effects of these medications.

 "US 7'387,806" .- Of Chinese inventor, this US patent describes a method used as a support compound during the treatment of cancer in mammals, based on geranium oil and Sophora ravensis root. As a difference with our invention we find that the elements mentioned here are not used in our formulation.

"PA 1993 005611 ^* .- Patent granted in Mexico to the company Abbott Laboratories which claims a nutritional product for people under treatment with chemo and radiotherapy. It stands out as a base ingredient of the formula, a hydrolyzate of soy protein, beta-carotene, carnitine, Taurine and a combination of fatty acids, elements that are not used in our formulation.

 3810382136 ".- Spanish inventor patent application that refers to the use of a Sigma ligand for the treatment of emesis induced by taxanes, vinca alkaloids or chemotherapeutic platinum drugs. Unlike our invention, which indicates this application It is limited only to treat emesis.

"WO 2013 048452" .- International patent application publication claiming the invention of a small molecule modulating the tumor necrosis alpha factor that reduces nephrotoxicity and hepatotoxicity caused by chemotherapy and radiotherapy treatments. Our formulation not only reduces these adverse effects but others that cause various unwanted manifestations in patients, allowing them to continue treatment. "WO 2009 084732" .- International patent application publication that reinvindicates a preparation based on potassium citrate and sodium citrate, used as a therapeutic agent to treat anemia, which is one of the adverse effects of treatment with combinations of Interferon and Rivavirine. Unlike this preparation, our formula fights a plurality of additional adverse effects, caused by therapies with interferons and antivirals.

 "WO 2008 021536" .- International patent publication describing a method to reduce unwanted adverse events in treatments with interferon alfa and interferon beta. The method consists mainly in the application of interferon tau orally simultaneously with the parenteral application of interferon alpha and interferon beta. This method particularly seeks to obtain a better response of the organism to interferon treatments, however a better response does not translate into a comprehensive improvement in the feeling of physical well-being of the patient, it improves that if it is achieved with the use of our formula when used simultaneously with the application of alpha and beta interferons.

BRIEF DESCRIPTION OF THE FIGURES FIG. 1 Shows a graph of the percentage of men and women participating in the study group of patients diagnosed with cancer who were undergoing chemotherapy, radiotherapy or both.

FIG. 2 Shows the age distribution of the group of patients diagnosed with cancer who participated in the study. FIG. 3 Shows the distribution by type of cancer of the patients who participated in the study. FIG. 4 It shows a comparative graph of the symptomatology of adverse effects manifested by patients diagnosed with cancer, without administering the formulation and that manifested after administering the formulation. FIG. 5 It shows a graph of the results at the end of the study with the group of patients diagnosed with cancer, where the number of patients under treatment and those without tumor activity (absence of disease, according to cabinet studies) can be seen. FIG. 6 It shows a comparative graph of the symptomatology of adverse effects manifested by patients diagnosed with HIV, without administering the formulation and that manifested after administering the formulation. DETAILED DESCRIPTION OF THE INVENTION

The present invention is a formulation composed of 101 ingredients of multiple different traces that are in different dilutions, ranging from the first dilution (1x) to the twelfth dilution (200x) making a total of 141 dilutions, of which 36% include source components vegetable that includes one or several elements of each of the following kinds of plants: agnoliopsides, liliopsides, equisetopsidas, lycopodiopsidas and pinopsidas, 14% are of animal origin where we find insects, nosodes and organotherapeutics; and 50% of mineral origin (trace elements and diluted inorganic chemical compounds of mineral origin) and other organic substances that include vitamins (coenzymes or cofactors), catalysts of the Krebs cycle and amino acids.

 The following describes all the components of the formulation; starting with the components of plant origin that are chosen from one of the following kinds of plants: Magnoliopsidas, Liliopsidas, Equisetopsidas, Lycopodiopsidas and Pinopsidas, which are extracted from trees, plants, fruits or roots that form 36% of the formulation and contains :

 1. Of 1 mg. at 5 mg Acidum acetylosalicylium (acetylsalicylic acid) at the tenth dilution (10x), is applied to conditions of weakness and muscle pain that may occur after chemotherapy.

 2. Of 1 mg. at 5 mg Avena sativa (oatmeal) at the sixth dilution (6x), is applied in nervous exhaustion due to chronic disease or by the application of chemotherapy.

 3. Of 1 mg. at 5 mg Baptisia tinctoría (wild indigo) at the fourth dilution (4x), is applied to mucosal ulcers (canker sores) that may appear post-chemotherapy.

4. Of 1 mg. at 5 mg of Barosma (Betulin) at the eighth dilution (8x), a natural diuretic that helps by inflammation of the post-chemotherapy genitourinary organs. 1 mg at 5 mg Bella donna atropa (belladonna) at the second dilution (2x), auxiliary in gastrointestinal colic after chemotherapy.

1 mg at 5 mg of Berberís vulgaris (barberry) at the fourth dilution (4x), auxiliary in urinary tree conditions after chemotherapy application.

1 mg at 5 mg of Beta vulgaris conditivo (Betabel) at the fourth dilution (4x), is a reactivator of cellular respiration that can be blocked after chemotherapy.

1 mg at 5 mg Bryonia (brionía) at the second dilution (2x), auxiliary in headache attacks with nausea, vomiting and desire to go to bed after chemotherapy.

1 mg at 5 mg Give Capsicum annuum (Spanish pepper) at the sixth dilution (6x), auxiliary in dyspepsia and flatulence accompanied by diarrhea after chemotherapy.

1 mg at 5 mg Carduus marianus (morning thistle) at the third dilution (3x), favors liver detoxification after chemotherapy application.

1 mg at 5 mg Chamomilla recutita (chamomile) at the third dilution (3x), auxiliary for states of restlessness and excitement after chemotherapy.

1 mg at 5 mg of Chelidonium majus (celandine) at the fourth dilution (4x), auxiliary in inflamed, painful liver irradiated to the back after chemotherapy application. 1 mg at 5 mg from China officinalis (quina bark) at the fourth dilution (4x), aiding in the distention of the belly by abundant post-chemotherapy gases.

2 mg at 6 mg of a first solution of Colchicum autumnale (colic) at the fourth dilution (4x), auxiliary in nausea and vomiting when smelling post-chemotherapy foods.

1 mg at 5 mg of a second solution of Colchicum autumnale (colic) at the sixth dilution (6x), auxiliary in nausea and vomiting when smelling post-chemotherapy foods.

1 mg at 5 mg of a first solution of Conium maculatum (hemlock) at the second dilution (2x), auxiliary in dizziness after having chemotherapy.

1 mg at 5 mg of a second solution of Conium maculatum (hemlock) at the third dilution (3x), auxiliary in dizziness after having chemotherapy.

1 mg at 5 mg of a third solution of Conium maculatum (hemlock) at the fourth dilution (4x), auxiliary in dizziness after having chemotherapy.

1 mg at 5 mg Cynara scolymus (artichoke) at the sixth dilution (6x), participates in the stimulation of the liver's detoxifying and natural diuretic function in post-chemotherapy edema.

1 mg at 5 mg of Equisetum hyemale (horsetail) at the fourth dilution (4x), auxiliary in the retention of urine, renal disease and urinary tract post-chemotherapy. 21. Of 1 mg. at 5 mg from a first solution of Galium aparine (hydrangea love) to the second dilution (2x), auxiliary in generalized edema that may appear post-chemotherapy.

 22. Of 1 mg. at 5 mg of a second solution of Galium aparine (hydrangea love) at the sixth dilution (6x), auxiliary in generalized edema that may appear post-chemotherapy.

 23. Of 1 mg. at 5 mg of a first solution of Hidrastis canadensis (hydrastis or gold seal) at the third dilution (3x), helps poor digestion, belching, nausea, vomiting after chemotherapy application.

 24. Of 1 mg. at 5 mg of a second solution of Hidrastis canadensis (hydrastis or gold seal) at the fourth dilution (4x), helps poor digestion, belching, nausea, vomiting after chemotherapy application.

25. Of 1 mg. at 5 mg of a first solution of Ipecacuanha (ipecacuana) at the fourth dilution (4x) auxiliary in nausea, vomiting, irritated stomach that may appear post-chemotherapy.

 26. 0.5 mg. to 3 mg of a second solution of Ipecacuanha (ipecacuana) at the twelfth dilution (12x) auxiliary in nausea, vomiting, irritated stomach that may appear post-chemotherapy.

27. 0.5 mg. to 3 mg of a third solution of Ipecacuanha (ipecacuana) at the thirtieth dilution (30x) auxiliary in nausea, vomiting, irritated stomach that may appear post-chemotherapy. 28. 0.5 mg. to 3 mg of a fourth solution of Ipecacuanha (ipecacuana) at the twelfth dilution (200x) auxiliary in nausea, vomiting, irritated stomach that may appear post-chemotherapy.

 29. Of 1 mg. at 5 mg Lycopodium ciavatum (lycopodium) at the fourth dilution (4x) auxiliary in excessive belly flatulence after chemotherapy.

 30. Of 1 mg. at 5 mg Nux vomica (nut nut) at the fourth dilution (4x) auxiliary in vomiting, stomach upset and bitter mouth that may appear post-chemotherapy.

31. Of 1 mg. at 5 mg from Orthosiphon stamineus (java tea) to the sixth dilution (6x) natural diuretic that helps the kidneys after chemotherapy.

 32. Of 1 mg. at 5 mg of Pareira brava (butua root) at the sixth dilution (6x) auxiliary in urinary conditions and cystitis that may appear after chemotherapy.

 33. Of 1 mg. at 5 mg of a first solution of Podophillum peltatum (podofilo) at the second dilution (2x) auxiliary in acute intestinal inflammation that may be accompanied by copious diarrhea after chemotherapy.

34. Of 1 mg. at 5 mg of a second solution of Podophillum peltatum (podofilo) at the fourth dilution (4x) auxiliary in acute intestinal inflammation that may be accompanied by copious diarrhea post-chemotherapy. 35. Of 1 mg. at 5 mg of Pulsatilla pratensis (pulsatila) at the sixth dilution (6x) auxiliary in vertigo and neuralgic pain that may appear after chemotherapy. 36. Of 1 mg. at 5 mg Sarsaparilla (sarsaparilla) at the sixth dilution (6x) auxiliary in kidney disease and post-chemotherapy urinary tract disorders.

 37. Of 1 mg. at 5 mg Solidago virgaurea (rod of St. Joseph) at the third dilution (3x) has a tropism by the kidneys helps the elimination of post-chemotherapy fluids.

 38. Of 1 mg. at 5 mg of Taraxacum officinale (dandelion) at the fourth dilution (4x) auxiliary in vertigo with heaviness and pressure in the head after chemotherapy.

39. Of 1 mg. at 5 mg of Terebinthina laricina (turpentine oil) at the sixth dilution (6x) auxiliary in inflammation of the kidneys that may or may not be accompanied by bleeding when urinating after chemotherapy.

 40. Of 1 mg. at 5 mg of a first solution of Thuja occidentalis (yours western) to the fourth dilution (4x) auxiliary in joint pain that may appear after the application of chemotherapy.

 41. 0.1 to 2 mg. of a second solution of Thuja occidentalis (yours western) to the twelfth dilution (12x) auxiliary in joint pain that may appear after the application of chemotherapy.

42. 0.1 mg. to 2 mg of a third solution of Thuja occidentalis (yours western) to the thirtieth dilution (30x) auxiliary in joint pain that may appear after the application of chemotherapy.

43. 0.1 mg. to 2 mg of a fourth solution of Thuja occidentalis (yours western) to the twelfth dilution (200x) auxiliary in pains joints that may appear after the application of chemotherapy.

 1 mg at 5 mg Vaccinium myrtillus (cranberry) at the fourth dilution (4x) auxiliary in catarrhal conditions, with inflammation of the intestines accompanied by post-chemotherapy diarrhea.

 0.5 mg to 3 mg from a first solution of Veratrum album (vedegambre) to the third dilution (3x) auxiliary in nausea and vomiting when smelling post-chemotherapy food.

1 mg at 5 mg from a second solution of Veratrum album (vedegambre) to the fourth dilution (4x) auxiliary in nausea and vomiting when smelling post-chemotherapy food.

0.5 mg to 3 mg from a third solution of Veratrum album (vedegambre) to the tenth dilution (10x) auxiliary in nausea and vomiting when smelling post-chemotherapy food.

0.5 mg to 3 mg from a fourth solution of Veratrum album (vedegambre) to the thirtieth dilution (30x) auxiliary in nausea and vomiting when smelling post-chemotherapy food.

0.5 mg to 3 mg from a fifth solution of Veratrum album (vedegambre) to the twelfth dilution (200x) auxiliary in nausea and vomiting when smelling post-chemotherapy food.

10 mg at 14 mg of a first solution of Viscum album (mistletoe) at the first dilution (1x) auxiliary in renal filtration disorders, with loss of albumin in the urine that may appear after the application of chemotherapy. 51. Of 4 mg. at 8 mg of a second solution of Viscum album (mistletoe) at the tenth dilution (10x) auxiliary in renal filtration disorders, with loss of albumin in the urine that may appear after the application of chemotherapy.

 52. Of 1 mg. at 5 mg of a third solution of Viscum album (mistletoe) to the twenty-eighth dilution (28x) auxiliary in renal filtration disorders, with loss of albumin in the urine that may appear after the application of chemotherapy.

 53. Of 1 mg. at 5 g. of a fourth solution of Viscum album (mistletoe) to the hundredth ninety-eighth dilution (198x) auxiliary in renal filtration disorders, with loss of albumin in the urine that may appear after the application of chemotherapy.

 54. Of 3 mg. at 7 mg of Abrotanum (Abrótano) at the fourth dilution (4x)

 auxiliary in lymphatic circulation disorders (lymphedema) due to radiotherapy.

The components of animal origin used in the formulation are remedies prepared by raw materials that are of animal origin where it can be used: dissected animals (gallbladder cantharis) is made from the dry dust of the insect and in some other cases, parts or secretions of them as Apisinum (bee venom).

Other elements that participate in a very important way are the Nosodes that are made of tissue, secretion, organisms, bacteria or viruses, whose virulence or toxicity has been eliminated and its use is mainly aimed at chronic degenerative conditions. And finally, organotherapy, which is a method that uses remedies prepared based on healthy animal organs where they are diluted and energized to produce a specific stimulation on the affected human organ. The principle of the identical organ is used, complementing with the homeopathic principle of similarity. The organ is administered in microdoses (infinitesimals) that causes only one activation reaction of the specific organ, without affecting other organs.

 These elements make up the formulation by 1% and contain:

INSECTS AND ANIMALS

1. Of 1 mg. at 5 mg Apisinum (Bee venom) at the eighth dilution (8x) auxiliary in states of albuminuria and nephritis after chemotherapy application.

 2. Of 1 mg. at 5 mg of Cantharis vesicatoria (Spanish fly) at the sixth dilution (6x) auxiliary in the treatment of irritation and inflammation of the digestive and urinary mucous membranes with burning pain after chemotherapy and post-radiotherapy.

 3. Of 3 mg. at 7 mg Sepia at the sixth dilution (6x) auxiliary in liver conditions such as liver steatosis and hepatitis, which are accompanied by hepatomegaly that appears due to antiviral medications or viruses.

NOSODES 1. Of 1 mg. at 5 mg of Bacterium Coli (Escherichia coli) at the thirteenth dilution (13x) auxiliary in urinary tract infections that may occur after the administration of chemotherapy.

 2. Of 1 mg. at 5 mg of Coxsackie Virus A (Coxsackie Virus) at the eighth dilution (8x), auxiliary in mucosal, urinary tract or upper respiratory tract conditions such as post-chemotherapy pseudo-influenza.

 3. Of 1 mg. at 5 mg Pyrogenium (pyrogen) at the hundredth ninety-eighth dilution (198x) to relieve the sensation of intense cold and chills with increased fever and pain in post-chemotherapy limbs.

ORGANOTHERAPICS

 1. Of 1 mg. at 5 mg of Colon at the tenth dilution (10x), auxiliary in inflammation of the mucosa of the colon after chemotherapy.

 2. Of 1 mg. at 5 mg of Corpus pineale (epiphysis) at the eighth dilution (8x) natural antitumor activity.

 3. Of 1 mg. at 5 mg of Duodenum (duodenum) at the tenth dilution (10x), auxiliary to treat inflammation of the duodenum after chemotherapy application.

 4. Of 1 mg. at 5 mg Fel tauri (bull bile) at the eighth dilution (8x) auxiliary in diarrhea and flatulence that may occur after chemotherapy.

5. Of 1 mg. and 5 mg. Adrenal gland (adrenal gland) at the tenth dilution (10x) allows hormonal balance at the post-chemotherapy cell level. 1 mg at 5 mg Hepar (liver) at the eighth dilution (8x) organotropism stimulating liver cells to detoxify post-chemotherapy.

0.1 to 2 mg of a first solution of Medulla ossis (bone marrow) at the tenth dilution (10x) auxiliary in anemia that may occur after the application of chemotherapy.

0.1 to 2 mg of a second solution of Medulla ossis (bone marrow) at the thirtieth dilution (D30) auxiliary in anemia that may occur after chemotherapy.

0.1 to 2 mg of a third solution of Medulla ossis (bone marrow) at the twelfth dilution (200x) auxiliary in anemia that may occur after chemotherapy.

1 mg at 5 mg Pancreas at the tenth dilution (10x) organotropism stimulates the cells of the pancreas for detoxification after chemotherapy.

1 mg at 5 mg Pyelon (renal pelvis) at the tenth dilution (10x) organotropism stimulates renal cells for post-chemotherapy detoxification.

1 mg at 5 mg of Thalamus opticus (optic thalamus) at the eighth dilution (8x) cell stimulation factor of central post-chemotherapy control functions.

1 mg at 5 mg from Thymus (thymus gland) to the tenth dilution (10x) organotropism to the lymphatic system in its function for post-chemotherapy detoxification. 14. Of 1 mg. at 5 mg Ureter to the tenth dilution (10x), organotropism to the ureters in their function in post-chemotherapy conditions.

 15. Of 1 mg. at 5 mg from Urethra (urethra) to the tenth dilution (10x) organotropism to the urethra as a function of post-chemotherapy conditions.

 16. Of 1 mg. at 5 mg from Vesica Fellea (gallbladder) to the tenth dilution (10x) organotropism of the gallbladder in its function for post-chemotherapy detoxification.

 17. Of 1 mg. at 5 mg of Urinary Vesica (urinary bladder) at the eighth dilution (8x) organotropism to the urinary bladder in its function for post-chemotherapy detoxification.

The components of mineral origin used in the formulation are extracted from metal ions (trace elements) and diluted inorganic chemical compounds of mineral origin and contain:

OLIGOELEMENTS

 1. Of 1 mg. at 5 mg Cuprum sulfuricum (copper sulfate) at the sixth dilution (6x) auxiliary in muscle cramps that may appear post-chemotherapy.

 2. Of 1 mg. at 5 mg Magnesium gluconicum (magnesium gluconate) at the tenth dilution (10x) trace element of enzymatic action for liver enzymes and post-chemotherapy energy production.

3. Of 1 mg. at 5 mg Magnesium oroticum (magnesium orotate) at the sixth dilution (6x) trace element of enzymatic action for liver enzymes and post-chemotherapy energy production. Diluted inorganic chemical compounds of mineral origin.

 1. Of 1 mg. at 5 mg of Argentum nitricum (silver nitrate) at the sixth dilution (6x) auxiliary in permanent anxiety tending to post-chemotherapy depression.

 2. 0.1 mg. to 2 mg from a first solution of Arsenicum album (arsenic trioxide) to the twelfth dilution (12x) auxiliary in depletion state after chemotherapy application.

 3. Of 1 mg. to 3 mg from a second solution of Arsenicum album (arsenic trioxide) to the twenty-eighth dilution (28x) auxiliary in depletion state after chemotherapy application.

 4. 0.1 mg. to 2 mg from a third solution of Arsenicum album (arsenic trioxide) to the thirtieth dilution (30x) auxiliary in a state of exhaustion after the application of chemotherapy.

 5. 0.1 mg. to 2 mg from a fourth solution of Arsenicum album (arsenic trioxide) to the twelfth dilution (200x) auxiliary in a state of exhaustion after the application of chemotherapy.

 6. Of 1 mg. at 5 mg of Calcium carbonicum hahnemanni (calcium carbonate) at the twenty-eighth dilution (28x) auxiliary in distention of the belly with abundant gases and colic after the application of chemotherapy.

7. Of 4 mg. at 8 mg Hepar sulfuris (calcium carbonate and sulfur flowers) at the tenth dilution (10x) stimulates the functions and helps detoxify the liver after chemotherapy. 1 mg at 5 mg of Mercurius sublimatus corrosivus (mercury chloride or mercury bichloride, corrosive sublimed) at the eighth dilution (8x) auxiliary in frequent urination to very painful urination, with burning in the post-chemotherapy urethra.

1 mg at 5 mg of a first solution of Sulfur (sulfur) at the eighth dilution (8x) auxiliary against painless, imperious diarrhea that may appear after chemotherapy.

1 mg at 5 mg of a second solution of Sulfur (sulfur) at the tenth dilution (10x) auxiliary against painless, imperious diarrhea that may appear after chemotherapy.

1 mg at 5 mg of a third solution of Sulfur (sulfur) at the thirteenth dilution (13x) auxiliary against painless, imperious diarrhea that may appear after chemotherapy.

6 mg at 10 mg Phosphorus (phosphorus) at the sixth dilution (6x) auxiliary in parenchymal diseases of the kidney with tubular alterations such as glomerulonephritis or nephrotic processes with urinary changes that appear due to antiviral medications. 6 mg to 10 mg of Causticum Hahnemanni (Incinerated potassium bisulfate and calcium hydroxide) at the fourth dilution (4x) auxiliary in inflammatory processes of the skin due to burns that accompany with changes in the joints (elbow and knee) where there are pains in muscle tissues and tendon retraction that can cause difficulty swallowing or breathing, changes in the throat and bladder injuries with urinary changes due to radiotherapy, telecobalt and radioactive isotopes.

The other organic substances used in the formulation are composed of vitamins, Krebs cycle catalysts and amino acids. These elements together with those of mineral origin make up the formulation in 50%, participating in the cellular metabolic processes in a catalytic way as in the framework of cellular respiration and obtaining energy (cycle of krebs), unblocking process and cellular detoxification and contain: Vitamins (coenzymes or cofactors) and Krebs cycle catalysts

 1. Of 1 mg. at 5 mg of a first solution of Acidum alpha-ketoglutaricum (alpha-ketoglutaric acid) at the eighth dilution (8x) auxiliary in the states of physical weakness after the application of chemotherapy.

 2. Of 1 mg. at 5 mg of a second solution of Acidum alpha-ketoglutaricum (alpha-ketoglutaric acid) at the tenth dilution (10x) auxiliary in the states of physical weakness after chemotherapy application.

 3. Of 1 mg. at 5 mg of a first solution of Acidum alpha-liponicum (lipoic acid) at the sixth dilution (6x) auxiliary in the states of physical weakness after the application of chemotherapy.

4. Of 4 mg. at 8 mg of a second solution of Acidum alpha-liponicum (lipoic acid) at the eighth dilution (8x) auxiliary in the states of physical weakness after the application of chemotherapy. 4 mg at 8 mg of Acidum ascorbicum (ascorbic acid) at the sixth dilution (6x) auxiliary for states of physical weakness after chemotherapy application.

1 mg at 5 mg of Acidum cis-aconticum (cis-aconitic acid) at the eighth dilution (8x) auxiliary for states of physical weakness after chemotherapy application.

1 mg at 5 mg of Acidum citricum (citric acid) at the eighth dilution (8x) auxiliary for states of physical weakness after chemotherapy application.

1 mg at 5 mg of a first solution of Acidum DL malicum (malic acid) at the eighth dilution (8x) auxiliary for states of physical weakness after chemotherapy application.

1 mg at 5 mg of a second solution of Acidum DL malicum (malic acid) at the tenth dilution (10x) auxiliary for states of physical weakness after chemotherapy application.

1 mg at 5 mg of a first solution of Acidum fumaricum (fumaric acid) at the eighth dilution (8x) auxiliary for states of physical weakness after chemotherapy application.

1 mg at 5 mg of a second solution of Acidum fumaricum (fumaric acid) at the tenth dilution (10x) auxiliary to the states of physical weakness after the application of chemotherapy.

1 mg at 5 mg of Acidum oroticum (orotic acid) at the sixth dilution (6x) auxiliary in the stimulation of the detoxifying function of the liver after the application of chemotherapy. 1 mg at 5 mg of Acidum sarcolacticum (sarcolactic acid) at the sixth dilution (6x) auxiliary in generalized muscle pain that may occur after chemotherapy.

1 mg at 5 mg of a first solution of Acidum succinicum (succinic acid) at the eighth dilution (8x) auxiliary in fatigue and weakness after the application of chemotherapy.

0.5 to 3 mg of a second solution of Acidum succinicum (succinic acid) at the tenth dilution (10x) auxiliary in fatigue and weakness after the application of chemotherapy.

0.5 to 3 mg of a third solution of Acidum succinicum (succinic acid) at the thirtieth dilution (30x) auxiliary in fatigue and weakness after chemotherapy application.

0.5 to 3 mg of a fourth solution of Acidum succininum (succinic acid) at the twelfth dilution (200x) auxiliary in fatigue and weakness after the application of chemotherapy.

1 mg at 5 mg of a first solution of Adenosinum triphosphoricum (adenosine triphosphate) at the sixth dilution (6x) energizes the consumption systems, auxiliary in post-chemotherapy weakness.

1 mg at 5 mg of a second solution of Adenosinum triphosphoricum (adenosine triphosphate) at the eighth dilution (8x) energizes the consumption systems, auxiliary in post-chemotherapy weakness. 4 mg at 8 mg of a third solution of Adenosinum triphosphoricum (adenosine triphosphate) at the tenth dilution (10x) energizes the consumption systems, auxiliary in post-chemotherapy weakness. 1 mg at 5 mg Anthrachinonum (anthraquinone) at the tenth dilution (10x) favors detoxification after chemotherapy.

1 mg at 5 mg of Barium oxalsuccinicum (oxalsuccinate bank) at the tenth dilution (10x) auxiliary to the states of physical weakness after chemotherapy application.

1 mg at 5 mg Cerium oxalicum (cerium oxalate) at the eighth dilution (8x) promotes the use of oxygen at the cellular level when post-chemotherapy decreases.

1 mg at 5 mg of a first solution of Coenzimum A (coenzyme A) at the eighth dilution (8x) auxiliary for when there is a state of post-chemotherapy depletion.

1 mg at 5 mg of a second solution of Coenzimum A (coenzyme A) at the tenth dilution (10x) auxiliary for when there is a state of post-chemotherapy depletion.

1 mg at 5 mg of Cyanocobalaminum (cyanocobalamin) at the fourth dilution (4x) co-factor for enzymatic functions and energy production post-chemotherapy and post-radiotherapy.

1 mg at 5 mg Glyoxalum (oxalic or glyoxal aldehyde) at the tenth dilution (10x) unlocks the energy-producing systems of post-chemotherapy and post-radiotherapy liver cells.

4 mg at 8 mg of Histaminum (histamine) at the tenth dilution (10x) auxiliary in dryness of mucous membranes with burning burning after chemotherapy. 29. Of 1 mg. at 5 mg Hydrochinonum (hydroquinone) at the eighth dilution (8x) decreases the fever that may occur after chemotherapy and radiotherapy.

 30. Of 1 mg. at 5 mg of a first solution of Manganum phosphoricum (manganese phosphate) at the sixth dilution (6x) auxiliary in depletion states that may occur after the application of chemotherapy and radiotherapy.

 31. Of 1 mg. at 5 mg of a second solution of Manganum phosphoricum (manganese phosphate) at the eighth dilution (8x) auxiliary in depletion states that may occur after the application of chemotherapy.

 32. Of 1 mg. at 5 mg Methylgfyoxalum (methyl glyoxal) at the tenth dilution (10x) unlocks the energy-producing systems of post-chemotherapy liver cells.

33. Of 1 mg. at 5 mg of a first solution of Nadidum (nad +) (nicotinamide adenine dinucleotide) at the eighth dilution (8x) auxiliary for the stimulation of final oxidation in the respiratory chain at the cellular level.

 34. Of 1 mg. at 5 mg of a second solution of Nadidum (nad +) (nicotinamide adenine dinucleotide) at the tenth dilution (10x) auxiliary for the stimulation of final oxidation in the respiratory chain at the cellular level.

35. Of 1 mg. at 5 mg Naphthochinonum (naphthoquinone) at the tenth dilution (10x) favors post-chemotherapy cell detoxification. 1 mg at 5 mg of a first solution of Natrium diethyioxalaceticum (sodium oxaloacetate) at the sixth dilution (6x) auxiliary in the states of weakness participating in the post-chemotherapy and post-radiotherapy energy producing systems.

1 mg at 5 mg of a second solution of Natrium diethyioxalaceticum (sodium oxalacetate) at the eighth dilution (8x) auxiliary in the states of weakness participating in the post-chemotherapy and post-radiotherapy energy producing systems.

From 1 mg, to 5 mg. of a third solution of Natrium diethyioxalaceticum (sodium oxalacetate) to the tenth dilution (10x) auxiliary in the states of weakness participating in the post-chemotherapy and post-radiotherapy energy producing systems.

1 mg at 5 mg of a first solution of Natrium pyruvicum (sodium pyruvate) at the eighth dilution (8x) active factor of the citric acid cycle for states of physical weakness post-chemotherapy and post-radiotherapy. 1 mg at 5 mg of a second solution of Natrium pyruvicum (sodium pyruvate) at the tenth dilution (10x) active factor of the citric acid cycle for states of physical weakness post-chemotherapy and post-radiotherapy.

4 mg at 8 mg of Nicotinamidum (nicotinamide) at the sixth dilution (6x) co-factor for enzymatic functions and energy production post-chemotherapy and post-radiotherapy.

1 mg at 5 mg Parabenzochinonum (para-benzoquinone) at the tenth dilution (10x) favors post-chemotherapy cell detoxification. 43. Of 4 mg. at 8 mg of Pyridoxinum hydrochloricum (pyridoxine) at the sixth dilution (6x) co-factor for enzymatic functions and energy production post-chemotherapy and post-radiotherapy.

 44. Of 4 mg. at 8 mg of Riboflavinum (riboflavin) at the sixth dilution (6x) co-factor for enzymatic functions and post-chemotherapy energy production.

 45. Of 4 mg. at 8 mg Thiaminum hydrochloricum (thiamine) at the sixth dilution (6x) co-factor for enzymatic functions and post-chemotherapy and post-radiotherapy energy production.

 46. Of 1 mg. at 5 mg Trichinoylum (inositol) at the tenth dilution (10x) favors post-chemotherapy cell detoxification.

 47. Of 1 mg. at 5 mg Ubichinonum (ubiquinone) at the tenth dilution (10x) favors post-chemotherapy cell detoxification. Amino acids

 1. Of 1 mg. at 5 mg of Cysteinum (cysteine) at the sixth dilution (6x) auxiliary in rhetorical disturbances or accumulation of chemotherapy.

The present invention is a formulation elaborated by the combination of the traces of 101 different elements which are of natural origin, where to each of them the principles of drug dilution are applied, having the specificity of dilution and weight in milligrams to remove the symptoms and / or specific signs of the most common adverse effects of chemotherapy such as: nausea, vomiting, headache, myalgia, asthenia and adinamia. By selecting the 101 different elements that participate in micro doses we classify them according to the sphere of action that they participate in the organism, that is, according to the same pharmacological effect that it causes, thus achieving a synergy between the different elements for each group, without these competing or antagonizing each other, and the final effect is different and superior with the sum of its parts where we have a greater pharmacological effect to remove the symptoms and / or signs of some adverse effects of chemotherapy, since a single element for example to remove nausea would be very little improvement, since it is required to potentiate the natural antiemetic effect because the toxic load of chemotherapy is very high, therefore we need to cover the different stages through which the process of appearance of the different adverse effects of chemotherapy is going on. Thus the present invention in its function in a global way integrated by the traces of the multiple elements, when entering the interior of the organism by the sublingual route is not separated, since it works together in groups, and these act at the same time in different spheres of action that often share chemicals and receptors. In this way we can place the different groups of elements that are participating according to the sphere of action as:

Detoxification and drainage

When toxins are able to bind to cellular structures and DNA, the entry and exit of the flow into the cell is blocked by natural self-protection mechanisms, therefore metabolic processes are greatly affected since the basic elements for performing or completing the process of basal metabolism of the organism are limited, therefore the common final pathway of cellular toxicity to often comes from the interruption of cellular respiration, certain toxins are able to directly decouple cellular respiration but above all the mechanism is through mitochondrial DNA damage. Many drugs, such as antiretroviral drugs used in AIDS, and chemotherapeutics can also cause damage to mitochondrial DNA. Here the formulation is useful as it contains the krebs cycle catalysts and these activate a respiratory chain transporter protein, managing to unlock and be able to participate effectively in the treatment of cellular toxicity. Similarly, quinones, glyoxal and methylglyoxalum are capable of depolymerizing compounds such as toxins when they are attached to the matrix structures and together with the rest of the trace elements that have this same detoxification and drainage function, they also do deep cell cleaning effect.

 Thus we managed to promote a better effect of the invention by keeping the toxins as clean as possible to the organism and as a consequence a better quality of life in the patient.

Cellular matrix:

The cellular matrix occupies all the extracellular spaces (spaces that exist between the cells) of the organism and is also called extracellular space with a gelatinous consistency and chemically constituted by a complex network of sugars and proteins that are polymerated and these are attached to the cell membrane which contains all membrane receptors, cell adhesion molecules, etc. Thus in the cellular matrix or extracellular space is the means by which cells obtain their nutrients and they eliminate their toxins due to normal metabolism; and this makes it a transit route, since the cellular metabolism that is carried out inside the cell (cellular mitochondria) interacts with the structures that are outside the cell (extracellular space or matrix) such as blood vessels (arterial and venous), lymphatic and free endings of vegetative nerve fibers, make it directly connected to the central nervous system. Therefore, since the extracellular space is a pre-cell element, it constitutes a molecular filter in all cells or cell complexes and therefore it is of utmost importance to keep it as clean as possible of toxins for its proper functioning.

 Some traces of elements that participate in detoxification and drainage specifically in the cell matrix:

 • Tumor gland (thymus)

 • Abrotanum (abrótano)

Traces of elements that participate in detoxification and drainage:

Liver

When the present invention reaches the hepatocyte (the main cell in the liver responsible for the detoxifying action), it helps to activate the processes of elimination of toxins (metabolites of chemotherapy), hepatic steatosis, hepatomegaly, hepatitis (adverse effects of antiviral drugs) and others that keep their functioning in imbalance, since this organ is one of the most important detoxification in the body, and metabolically the most complex (participates in the metabolism of cholesterol, glycolysis and glyconeogenesis, as well as providing coagulation factors and many plasma proteins, and the performance of hormones and fats). When the detoxifying action occurs in the hepatocyte and this is at a lower capacity to respond due to the toxic load, all traces that work in this sphere of action help the hepatocyte to be provided with two metabolic pathways to deal with soluble toxins. in fat, mainly. In the phase 1 pathway it deals with environmental toxins, drugs (chemotherapeutic and antiviral drugs) and the final products of our own metabolism are also processed here for excretion. Phase 1 includes the enzymes of the P450 enzyme system, which is a collection of mixed-function oxidases. Fat-soluble toxins are changed through oxidation, reduction and hydrolysis, so that they are more soluble in water and their excretion can be facilitated through the kidneys in a water-soluble way and for certain cofactors to fulfill their action and this is where The present invention works, providing them with trace elements, amino acids, vitamins and substances such as NADH; and also participate in the phase 2 pathway or conjugation pathway using substances rich in sulfhydryl groups to metabolize toxins, a number of these substances such as cysteine and taurine, as well as glutathione (which is formed from of glycine, glutamine and cysteine under the influence of a setenium-dependent enzyme) that also act as free radical scavengers and heavy metal chelators.

 • morning thistle (carduus marianus)

• liver (hepar) • cysteine (cysteinum)

 • artichoke (cynara scolymus)

 • celandine (chelidonium majus)

 • cholesterol (cholesterinum)

 • calcium carbonate and sulfur flowers (hepar sulfuris)

 • oratic acid (acidum oroticum)

 • bull bile (fel tauri)

 • sepia

Kidney

 In the kidney, toxins that have been made soluble in water by the liver are excreted, as well as some medications and heavy metals. Excretion through the kidney is an important part of the detoxification process, and in the present invention renal excretion function is supported through traces of elements that act in its sphere of action at the renal level such as sarsaparilla, equisetum hyemale, Berberis vulgaris, solidago virgaurea, elements that will also support the function of the adrenal glands, and thus the plant materials that have been used classically in botanical medicine to support renal function.

 The nosodes and proteins of bee venom (apisinum) make it candidates for immunomodulation, such as organotherapeutics that stimulate the repair of the structure of the damaged organ by a mechanism of the tropism effect for its recovery.

• betulin (barosma) • barberry (berberís vulgaris)

 • artichoke (cynara scolymus)

 • horsetail (equisetum hyemale)

 • hydrangea love (galium aparine)

 • histamine (histaminum)

 • mercury chloride (mercunus subiimates corrosivus)

 • java tea (orthosiphon stamineus)

 • butua root (pareira brava)

 • sarsaparilla (sarsaparilla)

 • rod of St. Joseph (solidago virgaurea)

 • turpentine oil (terebinthina laricina)

 • mistletoe (album viscum)

 • bee venom (apisinum)

 • bacterium coli (Escherichia coli)

 • coxsackie virus a

 • renal pelvis (pyelon)

 • ureter (ureter)

 • urethra (urethra)

 • urinary bladder (urinary bladder)

 • Phosphorus (phosphorus)

Energy producing systems

The group of energy producing systems corresponds to the traces of the intermediate catalysts that participate as inductors and activators related to the cycle of krebs or citric acid, being the most important source of energy of the cellular metabolism and that when this is affected by the toxic load of some medications, in this case the chemotherapeutic ones, the alterations of the enzymatic systems are presented , since many conventional drugs base their principle of action on the influence they exert on enzymes. In addition, it is especially the action of enzymes that is affected by the increasing load so that if an enzymatic function fails, both an accumulation of the metabolites, already existing before the corresponding enzymatic reaction, and a lack of substrates to metabolize after this reaction; therefore, we need to support the energy producing systems by administering intermediate catalysts of the kreb cycle, in this way the metabolism is activated again and the blocked cellular and enzymatic functions are restarted and for use in their sphere of therapeutic action, and due to their physiological relationships, the term "intermediate catalysts" is broader, which includes: a) the catalysts in the strict sense (enzymes), which are substances that participate in the repair of the balance of chemical reactions , but without entering themselves into their process mechanism; b) the corresponding substrates, intermediates and cofactors (which are trace elements and vitamins), where the catalysts are only activated by these cofactors, that is to say they become specifically functional. Therefore, given that enzymatic damage manifests primarily as an exacerbation of the adverse effects of chemotherapy and radiotherapy with lack of energy, such as adinamia, asthenia, tiredness, fatigue, etc., it is possible to correct it by adding integral way traces of elements that participate in the repair of the balance of chemical reactions.

 • beet (conditive beta vulgaris)

 • alpha-ketoglutaric acid (Acidum alpha-ketoglutaricum)

 • Lipoic acid (acidum alpha-liponicum)

 • ascorbic acid (Acidum ascorbicum)

 • cis-aconitic acid (Acidum cis-aconticum)

 • citric acid (Acidum citricum)

 • malic acid (acidum DL malicum)

 • fumaric acid (Acidum fumaricum)

 • sarcolactic acid (Sarcolactic Acidum)

 • succinic acid (Acidum succininum)

 • adenosine triphosphate (adenosinum triphosphoricum)

 • anthraquinone (anthrachinonum)

 • barium oxalsuccinate (barium oxalsuccinicum)

 • cerium oxalate (cerium oxalicum)

 • coenzyme A (Coenzyme A)

 • cyanocobalamin (cyanocobalaminum)

 • oxalic or glyoxal aldehyde (glyoxalum)

 • magnesium gluconate (magnesium gluconicum)

 • magnesium orotate (magnesium oroticum)

 • manganese phosphate (manganum phosphoricum)

 • methyl glyoxal (methylglyoxalum)

• nicotinamide adenine dinucleotide (nadidum nad +) • naphthoquinone (naphthochinonum)

 • sodium oxaloacetate (natrium diethyloxalaceticum)

 • sodium pyruvate (natrium pyruvicum)

 • nicotinamide (nicotinamidum)

 Para-benzoquinone (parabenzochinonum)

 • pyridoxine (pyridoxinum)

 • riboflavin (riboflavinum)

 • thiamine (thiaminum hydrochloricum)

 • inositol (trichinoylum)

 Ubiquinone (ubichinonum)

 • arsenic trioxide (album arsenic)

Nervous system

 The content of the traces of elements that are participating in the sphere of action at the nervous system level are because they have also been found other effects to treat a wide range of ailments, among which popularly include very specific properties such as sedatives , anticonvulsants to a lesser extent, without affecting the essential cognitive functions and orientation in time, place and space at the mental level, producing more an effect of emotional relaxation as a neuroprotective effect against global brain damage caused by oxidative stress induced by Chemotherapies and similarly generates a secondary muscle relaxant effect from a central level (central nervous system).

Traces of elements that participate at the nervous system level: • Avena Sativa (oats)

 • Chamomile (chamomilla recutita)

 • Cicuta (conium maculatum)

 • pulsatila (Pulsatilla pratensis)

 Epiphysis (corpus pineale)

 • Adrenal gland (adrenal gland)

 • Optical thalamus (thalamus opticus)

 • Silver nitrate (argentum nitricum)

 • Dandelion (Taraxacum officinale)

Muscle system - skeletal and smooth muscle

 Other adverse effects that usually occur after the application of chemotherapy and radiotherapy are disorders at the level of the smooth muscular system and skeletal muscle, since naturally all physical functions of the body involve muscular activity, and among them are skeletal movements, cardiac contraction, contraction of blood vessels and intestinal peristalsis and many more. These activities depend on three different types of muscles: striated, cardiac and smooth, all of them have certain common characteristics; for example, the contraction is almost equal or identical, on the other hand its contraction reactivity powers differ greatly in capacity, duration of the contraction and other characteristics, and each type is specially adapted for the work it performs.

In the case of striated muscles, skeletal movements are produced and the mobility of the different parts of the body is due to them; while the smooth muscle is in almost all internal organs of the body such as the gastrointestinal tract, gallbladder, urinary bladder, ureters, etc., and is usually different from that of one organ to another, that is to say in many different ways, even in reactions to the different types of stimuli, characteristics of their innervation and function. However, something that is important to note is that in both muscle systems (smooth and striated) the same chemicals produce muscle contractions, and the disorders that usually occur are caused by different causes and the reason is because the end result of multiple factors , although the triggering event may be as diverse as in neuroendocrine (fibromyalgia, insomnia), inflammatory (trauma or secondary to infectious foci) alterations, decreased perfusion (slow or claudizing gait) and by matrix toxicity, This last point is the one that corresponds to dealing with our molecule, since the great toxic load of chemotherapy here will also generate damage in an acute manner with manifestation of signs and symptoms at the level of the striated and smooth muscular system; In the latter, it is more evident in the gastrointestinal tract and urinary tract where the cellular matrix is altered, generating inflammatory processes with generalized pain that goes from minimal to strong incapacitating because fibroblasts are involved (organic part located in the extracellular space that is the center of main control of the matrix with the autonomic nervous system) where there is a restructuring with more acidosis and inflammation; Spasm (involuntary convulsive contraction of the muscles) is almost a measure of muscle protection that does not move, but causes more perfusion problems with inflammation and pain occurs. It should be mentioned that in the striated muscle the nervous system interacts with the muscle through a specialized structure called neuromuscular plaque, and in smooth muscle cells this plaque is not present, but instead there are terminal nerve branches that have vesicles and that these contain inside neurotransmitters that are released in the extracellular space; This is where the molecules diffuse to interact with the receptors of the smooth muscle cell membranes, then the contraction impulses sweep over the smooth muscle cells, because the cells communicate through the junctions. Smooth muscles mainly react to the autonomic nervous system stimuli through the autonomic receptor binding.

Autonomous or autonomous receivers are classified as:

A) Cholinergic receptors (use acetylcholine) and are subdivided into receptors: muscarinic or acetylcholine-muscarinic receptors (mAChR) such as M1, M2, 3 type found in smooth muscle, 4 M5 are found in the brain. And in nicotinics or acetylcholine-nicotinic receptors (nAChR) these can increase or decrease the activity of the effector cells.

 B) Adrenergic receptors (use catecholamines such as: epinephrine and norepinephrine).

Therefore, the present invention contains traces of elements that are antagonists of acetylcholine such as scopolamine and atropine found in Belladonna Atropa, all of which are tertiary or quaternary antimuscarinic aminos, which block the action of acetylcholine in the receptor. That can be used to control the secretion of saliva and gastric acid, slow intestinal motility and prevent vomiting, they also act as powerful antimuscarinic antispasmodics also used to block receptor 3, which is found in smooth muscle of hollow organs such as the digestive and respiratory system.

Muscle - skeletal apparatus

The appearance of skeletal muscle spasm is complex, and has its origin not only in the muscle itself, but also in the centers of the highest pain. Remission to deeper tissues is based on central nervous mechanisms. The neuromuscular junction in skeletal muscle is a highly specialized structure, where acetylcholine is the final neurotransmitter, however, not through muscarinic and nicotinic receptors as in the case of smooth muscle. When the nerve impulse reaches the motor plate, the activity of the motor nerve is transferred to the muscle fibers as a result of the contraction, the action potentials generated by the motor neurons, and carried out along the axon that cause the release of acetylcholine in the synaptic space. Acetylcholine binds to cholinergic receptors (acetylcholine), which opens up ion channels especially sodium channels, which reduces the membrane potential that results in muscle contraction. When there is injury to the muscle (in this case toxic load) the pain receptors are sensitive, reactive vessel substances are released causing edema, venous stasis and ischemia. This in turn leads to the loss of ATP, with the breakdown of the calcium pump in the muscle, which is responsible for the relaxation of muscle fibers the result is a spasm. When the situation continues the higher centers, such as the spinal cord and the middle brain, which are structures that change and lose their typical inhibitory influence on pain; This will lead to an increase in pain perception. In the scenario our molecule is thus part of a combination therapy and serves as an important link to break the vicious circle of pain and spasms due to the inclusion of diluted peptides from traces of plant elements, poisons (apisinum), organotherapeutic and nosodes that can induce regulatory T cells, such as TH3, that are regulated under TH1 helper cells. TH1 cells are activated in the inflammation and secretion of inflammatory cytokines and chemokines and while apisinum has an action in the inflammatory cascade by inhibiting COX-1 and COX-2, as well as LOX5 enzymes, which reduces formation of prostaglandins that act as chemical mediators.

 Traces of elements that participate at the level of the musculoskeletal system: acetylsalicylic acid (Acidum acetylosalicylicum)

 Tuya occidental (thuja occidentalis)

 Pyrogen (pyrogenium)

 Bone Marrow (Osulla Medulla)

 Copper sulfate (cuprum sulfuricum)

 sarcolactic acid (acidum sarcolacticum)

 Hydroquinone (hydrochinonum)

 Causticum Hahnemanni (Incinerated Potassium Bisulfate

calcic) Digestive system

Gastrointestinal disorders represent one of the most common reasons why patients seek medical attention, since these are nausea, vomiting, stomatitis with old mouth ulcerations, diarrhea or constipation, abdominal distension, flatulence, abdominal cramps ranging from minimum to be disabling, etc. That is why a large number of these complaints correspond to the functional category, the origin of these disorders can be multifactorial but what is responsible for this great diversity of gastrointestinal disorders is that they commonly occur as an adverse effect of chemotherapies either one or various conditions The mucosal surfaces against the greatest amount of antigens in front of the body have a very specific anatomical configuration in order to fulfill the delicate task of how to distinguish between harmful substances such as pathogenic bacteria, toxins, beneficial substances, food particles and bacteria diners To understand the pathological mechanisms in the gastrointestinal tract, we will generally review the normal physiology at play in the intestinal mucosa. The barrier of the gastrointestinal mucosa in order to be a highly selective filter and a bar at the same time, the lining of the intestines has to be a very specialized entity. There are 6 components that will prevent harmful substances such as antigens (chemotherapy metabolites), pathogenic bacteria and inflammation mediators from entering the body. These include the highly specialized epithelial barrier with tight junctions between cells, water without agitation and mucus layers, probiotic bacteria, immune system, endothelial wall as well as the liver. This together with the interaction of intestines-brain and intestine-endocrine system, form a perfect harmony in psycho-neuro-endocrine immunology.

 The non-agitated water and the mucus layer, as well as the probiotic bacteria form a passive barrier that prevents harmful substances from coming into contact with the epithelial layer. However, probiotic bacteria also have other functions, such as the fuel supply of mucous cells as well as contributing to immune competence.

 The absorption of particles through the epithelial layer is possible in 2 ways: through the transceíular epithelial cells, or paracellular through the narrow junction. The narrow junction has a complex physiology and only particles of a diameter are allowed to apply to certain sizes to enter, which varies in size in different physiological and pathological conditions.

 The mucosal immune system is the next line of defense and guarantees special attention for several reasons. Not only most of our competent immune cells located in Peyer's plaques, but the intestinal immune system also deals with antigens in a very specific way in order to develop oral tolerance to useful substances. This mechanism serves as a model for the immune modulating mechanism of our molecule's work in the immune assistance reaction.

The blood flow that forms is the next barrier, not only in the sense that it will carry residual toxins in the liver, but it seems that the endothelial layer also plays an important role in the permeability of the epithelial layer. The liver is one of the main detoxification organs in the body as already mentioned above, and it is beneficial that all the blood that flows from the intestine into the liver through the portal vein therefore the liver has a role in the development of tolerance to certain foods and jointly carrying the toxic load of metabolites generated by chemotherapeutic drugs together with the rest of the organs and especially more evident in the gastrointestinal tract (matrix and urinary system) our molecule contains elements that They will be very useful for having a double function in both the liver and the intestine. The rupture of any of these barriers will cause unwanted absorption and will penetrate deeply into much farther away sites generating a reabsorption of toxins with an exacerbation of the adverse effects increasing those of the gastrointestinal type already mentioned previously, therefore we can summarize that this is going To cause an overload of toxins, which eventually reach the matrix and the cell, the most serious version occurs when the permeability of the epithelial layer loses its selectivity.

The intestinal immune system has developed a special immune response to these toxins, which response is oriented towards tolerance, mucosal surfaces have a large number of regulatory T cells, of which TH3 cells and suppressor T cells are the most important for this purpose. TH3 cells are an important source of transforming growth factor beta and serves to restore the normal oscillatory balance between Th1 and Th2 cells. Th2 cells secrete IL-10 and IL-4, which also regulate the low inflammatory response, the normal response of the intestinal immune system tends to be that of a regulation or a response to TH2 cells.

 The Th3 cell is induced by small dilutions of amino acids contained in the present invention as trace elements of plants, poisons (apisinum), therapeutic organs and nosodes, which the clones of these cells (TH3 cell) will be attracted to chemokines to any site of inflammation that regulate a downward trend of TH1 cells and balance the ratio between Th1 / Th2, this regulatory action induced by the present invention, can be used not only in autoimmunity to induce tolerance to Affected tissues after administration of chemotherapy, but also to regulate with a downward trend in inflammation, not only in the intestine, but for the entire organism.

Traces of elements that participate at the level of the digestive system:

 • Wild Indigo (baptisia tinctoria)

 • Belladonna (Bella Donna Atropa)

 • Brionia (Bryonia)

 • Spanish pepper (capsicum annuum)

 • Quina bark (China officinalis)

 • cubic (colchicum autumnale)

 • gold seal (hydrastis canadensis)

 • histamine (histaminum)

 • ipecacuana (Ipecacuanha)

 • lycopodium (lycopodium)

• Vomical nut (Nux Vomical) • podophyll (podophillum peltatum)

 • vedegambre (veratrum album)

 • Spanish fly (cantharís vesicatoria)

 • colon (Colon)

 • duodenum (duodenum)

 • pancreas (pancreas)

 • gallbladder (vesica fellea)

 • calcium carbonate (calcium carbonicum hahnemanni)

 • sulfur (sulfur)

 • cranberry (vaccinium myrtillus)

 Achieving thus form a formulation from the combination of the different 101 elements that participate and therefore covers in a global way integrating most of the following possibilities of relief such as:

• the stimulation of blocked enzyme systems in digestive diseases, after the application of chemotherapy, radiotherapy and drug treatments with antivirals and interferons.

 • stimulation of defensive antitoxic mechanisms,

 • stimulation of central regulatory functions (hypothalamus-pituitary-adrenal gland),

 • stimulates the function of liver cells,

 • in gastrointestinal and hepatic functional disorders, together.

• stimulation of self-defense mechanisms in kidney and urinary tract conditions after the administration of chemotherapy, radiotherapy and antiviral medications and interferons, cell revitalization in those who are working at a lower capacity.

This medicine can be administered by different routes, mainly the sublingual, including oral, parenterally, as well as topically.

 The preferred method of administration for the treated cases is orally, which is prepared in the form of a sublingual tablet obtained by impregnating a solid support with the diluted drug formulation mentioned above. Lactose is used as solid support. Said tablet containing 438.40 mg of active ingredient.

 For administration, 1 or 2 tablets are dissolved under the tongue every 15 minutes for a period of 2 hours before chemotherapy, after chemotherapy dissolve 1 or 2 tablets every 15 minutes for 2 doses, continue with 1 or 2 tablets each 4 or 6 hours depending on the inconvenience for 7 days. In case of nausea and / or vomiting crisis, take 1 or 2 tablets every 15 minutes until the symptoms disappear for a maximum period of 2 hours.

 The results of cases treated with the formulation are described below, in a group of patients with different types of cancers, who were treated with some type of chemotherapy or radiotherapy, as well as in patients treated with antivirals and interferons to combat hepatitis C and HIV

It was observed that of the cases reviewed within a control group, 72% were female and 28% male as shown in FIG. . As shown in FIG. 2 the age range of the patients was varied, with a predominance of onset in the third decade of life.

 Of the patients studied, an increase was observed in the cases of breast, lymphoma and colon cancer, as shown in FIG. 3.

 Regarding breast cancer, it was found that right breast cancer was predominant with 77% of cases, as shown in FIG. 3.

 In the end, to demonstrate the benefit of using this product, a comparison was made of the cases studied according to their symptoms without taking the formulation compared with the cases in which the formulation was administered, the results are shown in FIG. Four.

 As shown in FIG. 5 it is observed that in the majority of the cases compared they have been without tumor activity, which does not indicate cure, but a total resolution of the tumor. The results of treatment with the formulation together with the standard cancer chemotherapy and / or radiotherapy regimens indicate that the components of the present invention can act to relieve symptoms and improve the quality of life of cancer patients.

In the case of patients with antiviral and interferon-based treatments, as can be seen in Figure 6, which shows the results obtained in a group of 9 patients infected with Human Immunodeficiency Virus (HIV) who agreed to be part of a protocol of research in 2009 (Dr. Enrique Gómez Bastidas. Amigo Program. Autonomous University of Baja California). This group of patients they were being treated with antiretroviral drugs, which also produce serious adverse effects to those who use them.

The study was conducted with the invitation of 12 people diagnosed with HIV, within the Program, of which only 9 managed to complete the study. Three were discarded due to treatment abandonment.

This type of patients when using antiretrovirals had very similar adverse effects than people receiving chemotherapies and radiotherapies, from nausea, vomiting and even peripheral neuropathies. The evaluation was done under the same format where most of the possible effects are recorded and where each of the patients designated and registered them, the same process that was used for patients with Cancer,

The results, although they were monitored for a shorter time than for cancer patients, were also surprising and hopeful for this group of patients as well, when using the formulation object of the present invention.

Claims

REI VI NDICATION EN Improvements to a diluted pharmaceutical formulation comprising at least one component of plant origin of the groups consisting of magnoliopsides, liliopsides, equisetopsides, lycopodiopsides and pinopsides; at least one component of animal origin of the groups formed by insects, nosodes and organotherapics; and at least one component of mineral origin of the groups consisting of trace elements, inorganic chemical compounds, organic substances of the group of vitamins (coenzymes or cofactors), catalysts of the cycle of krebs and amino acids, characterized in that it comprises as new components to improve the formula pharmaceutical, Abrotanum (abrotane); Phosporus; Causticum Hahnemanni (Incinerated potassium bisulfate and calcium hydroxide) and Sepia. The improvements to the pharmaceutical formulation according to claim 1, characterized in that the components of the formulation are previously made based on dilutions at different potencies. The improvements to the pharmaceutical formulation according to reinvindication 1, characterized in that within the diluted components of plant origin of the group of plants Magnoliopsidas, Liliopsidas, Equisetopsidas, Lycopodiopsidas and Pinopsidas includes the use of Abrotanum (abrótano) at the fourth dilution (4x) in an amount of 3 mg to 7 mg. The improvements to the pharmaceutical formulation according to claim 1, characterized in that the diluted components of animal origin comprise the use of Sepia at the sixth dilution (6x) in an amount of 3 mg to 7 mg; 5. The improvements to the pharmaceutical formulation according to claim 1, characterized in that the diluted components of mineral origin comprise: Phosphorus (phosphorus) at the sixth dilution (6x) in an amount of 6 mg to 10 mg; Y Causticum Hahnemanni (Incinerated potassium bisulfate and calcium hydroxide) at the fourth dilution (4x) in an amount of 6 mg to 10 mg. 6. An improved pharmaceutical formulation according to claims 3, 4 and 5, characterized by its use to counteract and alleviate the adverse effects of radiotherapy, applying a dose of 1 to 2 tablets every 15 minutes for 2 hours and continuing with 1 to 2 tablets every 4 or 6 hours for 7 days, after the application of radiotherapy. 7. An improved pharmaceutical formulation according to claims 3, 4 and 5, characterized by its use to counteract and alleviate the adverse effects of treatments with antiviral medications and / or interferons, applying a dose of 1 to 2 tablets every 15 minutes for 2 hours and continue with 1 to 2 tablets every 4 or 6 hours for the duration of treatment with antiviral medications and / or interferons.